Hiv env proteins

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 23: Line 23:
-
</StructureSection>
 
-
<StructureSection load='3p30' size='400' side='left' caption='crystal structure of the cluster II Fab 1281 in complex with HIV-1 gp41 ectodomain (PDB entry [[3p30]])' scene=''>
+
 
== gp41 ==
== gp41 ==
gp41 is a transmembrane protein on the viral envelope of HIV, with its "C-terminal transmembrane segment inserted in the viral membrane" and its N-terminal outside the viral membrane beneath the gp120 proteins <ref name=Guan>PMID: 21076402 </ref>. gp41 facilitates fusion of HIV with the host cell. There are 3 different conformations that gp41 can exist in: prefusion state, prehairpin intermediate, and post fusion state. In the prefusion state gp41 exists as the transmembrane segment mentioned above. Upon binding of gp120 to CD4, gp41 enters the prehairpin intermediate, where it extends into the host cell and the C-terminal segment remains in the viral envelope. Further rearrangement induces the post fusion state, where gp41 is completely enters the host cell, causing fusion of the membranes. [[Image:Structure complex gp41-post 1281Fab.png|thumb|right|<ref name=Guan>PMID: 21076402 </ref>]] There are three main types of antibodies that can potentially bind gp 41: MPER antibodies, cluter I antibodies, and cluster II antibodies. These are either neutralizing antibodies or non-neutralizing antibodies. MPER "neutralizing antibodies target a region on gp41 adjacent to the viral membrane, called the <scene name='Hiv_env_proteins/Gp41_mper/1'>membrane-proximal external region</scene> (MPER)" represented by the red region <ref name=Guan>PMID: 21076402 </ref>. Two broadly neutralizing proteins that target this region in the prehairpin-intermediate state are: 4E10 and 2F5. However, non-neutralizing antibodies are more prevalent in infected individuals. Cluster I antibodies target a part of gp41 that is not readily accessible while "Cluster II antibodies recognize another <scene name='Hiv_env_proteins/Gp41_mper/2'>immunodominant segment</scene> (residues 644–663) next to the MPER" <ref name=Guan>PMID: 21076402 </ref>. Cluster II antibodies are non-neutralizing because they bind to gp41 in the <scene name='Hiv_env_proteins/Gp41_181_interaction/1'>post fusion</scene> conformation, after the fusion is already complete or when gp120 proteins are prematurely shed. Cluster II epitopes, like the six alpha helix bundle, facilitate HIV-1 immune evasion by triggering the production cluster II antibodies that are non-neutralizing. "HIV-1 may thereby exploit the envelope stability as one of its immune-evasion tactics to distract the immune system from the native, functional trimers" <ref name=Guan>PMID: 21076402 </ref>. "The stable postfusion conformation of gp41 probably serves as a decoy to help HIV-1 evade the immune system and induce ineffective antibody responses in infected people. It has been shown that unique B-cell clones targeting cluster II epitopes account for 49% of all anti-gp41-reactive B cells" <ref name=Guan>PMID: 21076402 </ref>.
gp41 is a transmembrane protein on the viral envelope of HIV, with its "C-terminal transmembrane segment inserted in the viral membrane" and its N-terminal outside the viral membrane beneath the gp120 proteins <ref name=Guan>PMID: 21076402 </ref>. gp41 facilitates fusion of HIV with the host cell. There are 3 different conformations that gp41 can exist in: prefusion state, prehairpin intermediate, and post fusion state. In the prefusion state gp41 exists as the transmembrane segment mentioned above. Upon binding of gp120 to CD4, gp41 enters the prehairpin intermediate, where it extends into the host cell and the C-terminal segment remains in the viral envelope. Further rearrangement induces the post fusion state, where gp41 is completely enters the host cell, causing fusion of the membranes. [[Image:Structure complex gp41-post 1281Fab.png|thumb|right|<ref name=Guan>PMID: 21076402 </ref>]] There are three main types of antibodies that can potentially bind gp 41: MPER antibodies, cluter I antibodies, and cluster II antibodies. These are either neutralizing antibodies or non-neutralizing antibodies. MPER "neutralizing antibodies target a region on gp41 adjacent to the viral membrane, called the <scene name='Hiv_env_proteins/Gp41_mper/1'>membrane-proximal external region</scene> (MPER)" represented by the red region <ref name=Guan>PMID: 21076402 </ref>. Two broadly neutralizing proteins that target this region in the prehairpin-intermediate state are: 4E10 and 2F5. However, non-neutralizing antibodies are more prevalent in infected individuals. Cluster I antibodies target a part of gp41 that is not readily accessible while "Cluster II antibodies recognize another <scene name='Hiv_env_proteins/Gp41_mper/2'>immunodominant segment</scene> (residues 644–663) next to the MPER" <ref name=Guan>PMID: 21076402 </ref>. Cluster II antibodies are non-neutralizing because they bind to gp41 in the <scene name='Hiv_env_proteins/Gp41_181_interaction/1'>post fusion</scene> conformation, after the fusion is already complete or when gp120 proteins are prematurely shed. Cluster II epitopes, like the six alpha helix bundle, facilitate HIV-1 immune evasion by triggering the production cluster II antibodies that are non-neutralizing. "HIV-1 may thereby exploit the envelope stability as one of its immune-evasion tactics to distract the immune system from the native, functional trimers" <ref name=Guan>PMID: 21076402 </ref>. "The stable postfusion conformation of gp41 probably serves as a decoy to help HIV-1 evade the immune system and induce ineffective antibody responses in infected people. It has been shown that unique B-cell clones targeting cluster II epitopes account for 49% of all anti-gp41-reactive B cells" <ref name=Guan>PMID: 21076402 </ref>.

Revision as of 12:47, 15 January 2015

Molecular structure for the HIV-1 gp120 trimer in the unliganded state (PDB entry 3dnn)

Drag the structure with the mouse to rotate



Other Research

There is currently no cure or vaccine for HIV. Thus, there are constantly new studies being conducted, that explore various aspects of HIV. One recent study done at the University of Amsterdam, explored the evolution of HIV post-infection and discovered that HIV can evolve glycan structures that induce the production of broadly cross neutralizing (BCN) antibodies. "The role of glycans in shielding neutralizing epitopes has long been known but it has only recently become clear that many BCN responses directly target glycans, including the one that evolves at on the gp120 construct"[5].



</StructureSection>


References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Frey G, Chen J, Rits-Volloch S, Freeman MM, Zolla-Pazner S, Chen B. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol. 2010 Dec;17(12):1486-91. Epub 2010 Nov 14. PMID:21076402 doi:10.1038/nsmb.1950
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008 Sep 4;455(7209):109-13. Epub 2008 Jul 30. PMID:18668044 doi:10.1038/nature07159
  3. 3.0 3.1 3.2 Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998 Jun 18;393(6686):648-59. PMID:9641677 doi:10.1038/31405
  4. 4.0 4.1 4.2 4.3 Chen L, Do Kwon Y, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009 Nov 20;326(5956):1123-7. PMID:19965434 doi:326/5956/1123
  5. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Karim QA, Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov;18(11):1688-92. doi: 10.1038/nm.2985. Epub 2012 Oct 21. PMID:23086475 doi:10.1038/nm.2985

Proteopedia Page Contributors and Editors (what is this?)

Nicholas Flores, Michal Harel, Alexander Berchansky

Personal tools